DCPH Stock Cash Flow Statements

Deciphera Pharmaceuticals Quarterly Cash Flow Statements Chart

Quarterly

Annual

Stock-Based Compensation

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Free Cash Flow

Capital Expenditure

Deciphera Pharmaceuticals Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31

cash flows from operating activities:
net income	-45,083,000	-47,190,000	-49,581,000	-48,562,000	-49,609,000	-45,935,000	-43,043,000	-43,061,000	-46,892,000	-88,395,000	-79,838,000	-70,433,000	-61,298,000	-62,740,000	-63,701,000	-67,241,000	-72,807,000	-67,216,000	-56,196,000	-21,460,000	-47,384,000	-32,299,000	-24,435,000	-21,690,000	-21,430,000	-19,912,000
adjustments to reconcile net income to net cash flows used in operating activities:
stock-based compensation expense	10,174,000	14,073,000	11,160,000	12,856,000	12,514,000	12,313,000	12,373,000	12,988,000	14,268,000	10,794,000	11,794,000	12,371,000	11,119,000	9,706,000	9,828,000	10,609,000	6,994,000	5,345,000	4,729,000	4,107,000	6,229,000	2,805,000	2,614,000
depreciation expense	450,000	456,000	465,000	571,000	608,000	601,000	742,000	820,000	783,000	780,000	759,000	743,000	732,000	695,000	666,000	484,000	460,000
noncash lease expense	1,147,000	1,136,000	1,124,000	1,113,000	1,102,000	1,091,000	1,081,000	1,000,000	954,000	919,000	852,000	842,000	833,000	886,000	886,000
net amortization of (discounts) premium on marketable securities	-1,653,000			-1,953,000	-1,566,000
changes in operating assets and liabilities:
accounts receivable	-878,000	-4,167,000	-4,489,000	-766,000	77,000	1,230,000	2,383,000	-2,836,000	-2,561,000	-2,546,000	559,000	3,213,000	-7,925,000	-2,082,000	-4,430,000
inventory	-918,000	972,000	3,531,000	-3,631,000	-1,258,000	-3,363,000	3,165,000	-1,443,000	-5,468,000	-6,880,000	881,000	-6,129,000	1,973,000	-786,000	-1,657,000
prepaid expenses and other current assets	-1,967,000	2,171,000	3,901,000	1,797,000	-4,061,000	-11,544,000	4,026,000	-148,000	-1,844,000	-2,694,000	-2,751,000	568,000	-3,057,000	-2,802,000	1,176,000	-1,999,000	1,853,000	-9,894,000	-1,690,000	-1,907,000	3,170,000	-2,539,000	-2,438,000	-980,000	187,000	-832,000
other long-term assets	140,000	-4,935,000	0			-1,000	-7,000
accounts payable	-6,944,000	4,933,000	3,272,000	-1,421,000	993,000	5,569,000	-3,386,000	-1,549,000	4,685,000	-345,000	-533,000	2,144,000	-433,000	2,375,000	-2,852,000	1,455,000	-8,511,000	4,400,000	870,000	2,963,000	2,629,000	2,257,000	-491,000	1,083,000	1,142,000	1,465,000
accrued expenses and other current liabilities	-8,196,000	5,992,000	3,649,000	2,234,000	-7,464,000	5,829,000	3,199,000	-10,382,000	-14,830,000	21,462,000	10,359,000	4,848,000	-9,384,000	5,584,000	10,775,000	4,364,000	-6,800,000	12,151,000	4,799,000	4,602,000	2,637,000	2,640,000	-435,000
operating lease liabilities	-857,000	-829,000	-813,000	-803,000	-791,000	-763,000	-749,000	-720,000	-702,000	-661,000	-626,000	-616,000	-607,000	-203,000	-185,000	-390,000	-555,000	127,000	-97,000	-201,000	-148,000
net cash flows used in operating activities	-54,585,000	-28,809,000	-29,807,000	-38,626,000	-49,455,000	-35,158,000	-20,828,000	-45,524,000	-51,352,000	-67,176,000	-53,999,000	-51,967,000	-67,682,000	-49,128,000	-49,341,000	-60,844,000	-80,370,000	-55,833,000
cash flows from investing activities:
purchases of marketable securities	-20,264,000	-59,657,000	-33,780,000	-106,275,000	-122,860,000	-82,175,000	-58,707,000			-21,657,000	-101,597,000	-180,296,000	-31,825,000	-127,764,000	-150,823,000	-614,655,000	-203,527,000	-198,952,000	-364,431,000	-74,152,000	-179,607,000
maturities of marketable securities	83,041,000	61,919,000	75,245,000	110,929,000	87,021,000	98,460,000	53,209,000	77,978,000	59,652,000	108,511,000	99,464,000	104,242,000	156,370,000	175,250,000	129,400,000	120,143,000	203,120,000
sales of marketable securities		0	0	0	785,000					10,996,000	22,584,000			0	24,470,000
purchases of property and equipment	-146,000	-63,000	-62,000	-293,000	-360,000	19,000	-573,000			1,109,000	-2,010,000	-432,000	-637,000	-430,000	-1,233,000	-2,984,000	-669,000	-1,725,000	-2,966,000	-203,000	-41,000	-303,000	-216,000	-455,000	-151,000	-130,000
net cash flows from investing activities	62,631,000	2,199,000			-35,414,000	16,304,000	-6,071,000	-104,194,000	59,652,000	98,952,000	14,441,000	-60,453,000	123,908,000
cash flows from financing activities:
proceeds from offerings of common stock, net of underwriting discounts and commissions		0	14,622,000	0	135,125,000					1,000	0	0	8,588,000
proceeds from pre-funded warrant exercise	9,000		0	0	24,000		6,000
payments of offering costs			0	0	-634,000		0				0
proceeds from stock option exercises and employee stock purchase plan	513,000	890,000	968,000	838,000	171,000	478,000	203,000	868,000	83,000	1,977,000	1,706,000
net cash flows from financing activities	522,000	890,000	15,590,000	838,000	134,686,000	478,000	209,000	164,224,000	83,000	1,978,000	1,706,000	1,682,000	9,524,000	27,792,000	3,228,000	4,389,000	191,392,000	761,000
net increase in cash and cash equivalents	8,568,000	-25,720,000	27,186,000	-33,427,000	49,817,000			14,506,000	8,383,000			-110,738,000	65,750,000	24,743,000	-44,292,000	-74,206,000	109,332,000	-53,392,000	116,475,000			-27,111,000	-25,652,000			114,605,000
effect of exchange rate changes on cash and cash equivalents	-847,000	1,140,000	-493,000	184,000	79,000	579,000	-470,000	-140,000	-114,000	120,000	94,000	37,000	1,000
cash and cash equivalents at beginning of period	83,507,000	0	0	0	64,741,000	0	0	0	87,063,000	0	0	0	135,897,000	0	0	0	120,320,000	0	0	0	293,764,000	0	0	0	196,754,000	0
cash and cash equivalents at end of period	91,228,000	-24,580,000	26,693,000	-33,243,000	114,637,000	-17,797,000	-27,160,000	14,366,000	95,332,000	33,874,000	-37,758,000	-110,701,000	201,648,000	24,743,000	-44,292,000	-74,206,000	229,652,000	-53,392,000	116,475,000	-24,991,000	82,228,000	-27,111,000	-25,652,000	166,654,000	179,873,000	114,605,000
adjustments to reconcile net income to net cash from operating activities:
acquired in-process research and development										0
net amortization (accretion) of premiums (discounts) on marketable securities
income tax liabilities
increase in restricted investments														-977,000	0	-1,000	-614,000	0	0			0	0
proceeds from pre-funded warrants
payments of public offering costs														-163,000	0	-300,000	-352,000	-267,000				0
net accretion of discounts on marketable securities														239,000	160,000	-478,000	-1,532,000	-1,729,000	-973,000	-811,000	-486,000
net cash flows used in investing activities															1,821,000	-17,751,000	-1,690,000	1,680,000
gain on disposal of equipment
proceeds from sale of equipment														0
proceeds from offerings of common stock and pre-funded warrants, net of underwriting discounts and commissions							0
net decrease in cash and cash equivalents																					-211,536,000				-16,881,000
net amortization (accretion) of premium (discounts) on marketable securities								-33,000	255,000		545,000	482,000	365,000
other long-term liabilities																		13,000	102,000	135,000	100,000	169,000	165,000	39,000	-5,000	-5,000
repayment of notes payable to related party																		-1,154,000	-47,000	-62,000	-31,000	-47,000	-47,000	-47,000	-46,000	-47,000
supplemental disclosure of cash flow information:
cash paid for interest																		12,000	17,000	25,000	13,000	20,000	21,000	21,000	22,000	23,000
addition of operating lease asset included in accrued expenses and other current liabilities
supplemental disclosure of non-cash investing and financing activities:
purchases of property and equipment included in accounts payable and accrued expenses and other current liabilities
unsettled exercise of stock options
(gain) loss on disposal of equipment
operating lease liabilities arising from obtaining operating lease assets
proceeds from exercise of stock options													936,000		3,228,000	4,827,000	2,569,000	2,182,000	2,476,000	81,000	1,149,000	107,000	91,000	707,000	10,000
proceeds from public offerings, net of underwriting discounts and commissions														18,194,000	0	-138,000	189,175,000	0
amounts capitalized under build-to-suit lease transaction																						-5,989,000	846,000
property and equipment purchases included in accounts payable and accrued expenses and other current liabilities															-209,000	373,000	152,000
offering costs included in accounts payable and accrued expenses and other current liabilities																	438,000
unbilled receivables
inventory purchases included in accrued expenses and other current liabilities
operating lease assets																	528,000	525,000
loss on disposal of property and equipment																										0
proceeds from issuance of convertible preferred shares																										0
payments of convertible preferred share issuance costs																										0
retirement of assets
conversion of convertible preferred shares into common stock
depreciation and amortization expense																			169,000	112,000	104,000	99,000	88,000	74,000	56,000	49,000
maturities and sales of marketable securities																			72,587,000
amounts capitalized under build-to-suit lease transactions
property and equipment purchases included in accrued expenses and other current liabilities
offering costs included in accrued expenses and other current liabilities
unbilled receivable
operating lease, right-of-use assets																				194,000	143,000
net cash from operating activities																				-37,266,000	-33,006,000	-26,868,000	-24,932,000	-18,289,000	-16,694,000	-12,753,000
capex																				-203,000	-41,000	-303,000	-216,000	-455,000	-54,000	-130,000
free cash flows																				-37,469,000	-33,047,000	-27,171,000	-25,148,000	-18,744,000	-16,748,000	-12,883,000
net cash from investing activities																				12,256,000	-179,648,000	-303,000	-216,000	-1,524,000	-151,000	-130,000
net cash from financing activities																				19,000	1,118,000	60,000	-504,000			127,488,000
supplemental disclosure of non-cash investing activities:
supplemental disclosure of non-cash financing activities:
offering costs included in accounts payable and accrued expenses
purchases of property and equipment included in accounts payable and accrued expenses
other assets
proceeds from follow-on public offering, net of underwriting discounts and commissions																							1,000
purchases of property and equipment included in accounts payable																									97,000
offering costs included in accounts payable or accrued expenses
payments of follow-on public offering costs
payments of initial public offering costs																										-1,577,000
share-based compensation expense																									2,037,000	2,844,000
accrued expenses																									1,319,000	3,638,000
net cash used by financing activities																									-36,000
deferred offering costs included in accounts payable or accrued expenses
non-cash interest expense
proceeds from initial public offering, net of underwriting discounts and commissions
proceeds from issuance of convertible notes payable to related parties
conversion of notes payable and accrued interest into convertible preferred shares
conversion of member units into series a convertible preferred shares
gain on extinguishment of notes payable to related party
purchases of property and equipment included in accounts payable or accrued expenses

We provide you with 20 years of cash flow statements for Deciphera Pharmaceuticals stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Deciphera Pharmaceuticals stock. Explore the full financial landscape of Deciphera Pharmaceuticals stock with our expertly curated income statements.

The information provided in this report about Deciphera Pharmaceuticals stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.